FourThought Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

FourThought Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-683	Closed	-$21K	–	1588
2022 Q2	$21K	Buy	683 +100	+17%	+$2.98K	﹤0.01%	866
2022 Q1	$19K	Hold	583	–	–	﹤0.01%	920
2021 Q4	$15K	Hold	583	–	–	﹤0.01%	997
2021 Q3	$58K	Buy	583 +214	+58%	+$25.1K	0.01%	648
2021 Q2	$52K	Hold	369	–	–	0.01%	695
2021 Q1	$36K	Sell	369 -57	-13%	-$6.65K	0.01%	772
2020 Q4	$52K	Buy	+426	New	+$56K	0.01%	655

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FourThought Financial's RETA Position: Q3 2022 in Review

FourThought Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 683 shares — an estimated $21K sold.

FourThought Financial first reported a position in RETA in Q4 2020 and held it in 7 quarters. The position peaked at $58K in Q3 2021. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

FourThought Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
FourThought Financial sold 683 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $21K.
FourThought Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 7 quarters.
FourThought Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $58K in Q3 2021.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.